🗓️Journée mondiale de la #scleroseenplaques 📚Revue @cochranecollab évaluant les bénéfices, les risques et la tolérabilité de l'ocrélizumab chez les personnes atteintes de #SEP 💻Résumé disponible sur @CochraneLibrary 🔗https://t.co/h6Nm94nr3S
RT @CochraneNursing: 🤔Are there any benefits or risks associated with the use of #ocrelizumab as a treatment for #MultipleSclerosis? Review…
RT @CochraneNursing: 🤔Are there any benefits or risks associated with the use of #ocrelizumab as a treatment for #MultipleSclerosis? Review…
RT @CochraneNursing: 🤔Are there any benefits or risks associated with the use of #ocrelizumab as a treatment for #MultipleSclerosis? Review…
RT @CochraneNursing: 🤔Are there any benefits or risks associated with the use of #ocrelizumab as a treatment for #MultipleSclerosis? Review…
🤔Are there any benefits or risks associated with the use of #ocrelizumab as a treatment for #MultipleSclerosis? Review the latest evidence about its outcomes, including relapse rates, disability progression, and adverse events here🖇https://t.co/10qeAWrMQd
Ein Cochrane Review zeigt, dass #Ocrelizumab bei #MS tatsächlich besser wirkt als die Standardtherapie. https://t.co/Te1zs57YMr Das hat allerdings auch seinen Preis: 33.000 Euro pro Jahr, das Zehnfache des zuvor off label genutzten Vorgängers. Siehe auch:
What are the benefits and risks of #ocrelizumab for #MultipleSclerosis? This @CochraneLibrary #SystematicReview evaluates the evidence from 4 studies with 2551 people with #MS. >> https://t.co/uCu1xwJNlC https://t.co/bebMdo9ZlL
RT @WileyNeuro: What are the benefits and risks of #ocrelizumab for #MultipleSclerosis? This @CochraneLibrary #systematicreview evaluates…
What are the benefits and risks of #ocrelizumab for #MultipleSclerosis? This @CochraneLibrary #systematicreview evaluates the evidence from 4 studies w 2551 people with #MS. 📃 https://t.co/wjrdVqlTwB https://t.co/BmmS5gYbiH
💊 What are the benefits and risks of #ocrelizumab for #MultipleSclerosis? This #systematicreview evaluates the evidence from 4 studies w 2551 people with #MS 📃 https://t.co/8DQFsKlf5f https://t.co/483sD1gBr8
New article: Ocrelizumab for multiple sclerosis https://t.co/zKzVYgzPhH #MS #multiplesclerosis #neurology https://t.co/0FKRZFDxvz